ONCOGENEX PHARMACEUTICALS IN's ticker is OGXI and the CUSIP is 68230A106. A total of 55 filers reported holding ONCOGENEX PHARMACEUTICALS IN in Q4 2015. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $11,000 | +57.1% | 10,663 | 0.0% | 0.00% | – |
| Q1 2016 | $7,000 | -46.2% | 10,663 | +0.9% | 0.00% | – |
| Q4 2015 | $13,000 | -43.5% | 10,563 | +5.3% | 0.00% | – |
| Q2 2015 | $23,000 | +4.5% | 10,036 | -2.0% | 0.00% | – |
| Q1 2015 | $22,000 | -4.3% | 10,236 | 0.0% | 0.00% | – |
| Q4 2014 | $23,000 | -14.8% | 10,236 | 0.0% | 0.00% | – |
| Q3 2014 | $27,000 | – | 10,236 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 603,740 | $5,917,000 | 4.55% |
| TANG CAPITAL MANAGEMENT LLC | 933,100 | $9,144,000 | 3.60% |
| JAY JEFFREY R | 347,004 | $3,401,000 | 2.69% |
| RA Capital Management | 863,332 | $8,461,000 | 1.12% |
| QVT Financial LP | 400,000 | $3,920,000 | 0.26% |
| SABBY MANAGEMENT, LLC | 396,730 | $3,888,000 | 0.26% |
| J. Goldman & Co LP | 222,907 | $2,184,000 | 0.22% |
| J. Goldman & Co LP | 156,000 | $1,529,000 | 0.16% |
| Tekla Capital Management LLC | 113,100 | $1,108,000 | 0.15% |
| Visium Asset Management, LP | 445,698 | $4,368,000 | 0.10% |